Kezar (KZR) stock fell 11% after the company's board rejected an unsolicited takeover offer from Concentra Biosciences and ...
Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra ...
On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...
Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to ...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its ...
(RTTNews) - Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to acquire all of the outstanding shares of common ...
After careful consideration and with the assistance of its independent financial and legal advisors, the Board unanimously concluded that the Concentra proposal substantially undervalues the Company.
Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company offers occupational and consumer health services, including workers’ compensation ...